Severance hospital
Seoul, 120750, South Korea
NCT Number: NCT00832689
The study hypothesis is that chemotherapy of irinotecan and gemcitabine will improve local control of cancer and prolong survival in patients with inoperable biliary tract cancer.
Looking for future studies?
Notify Me17 year–75 year
All sexes
Interventional
Phase 2
Seoul, 120750, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Looking for future studies?
Notify MeYonsei University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05835778
Biliary Tract Cancer, Biliary Tract Diseases
Aichi, Japan
View Trial DetailsNCT05297903
Biliary Tract Cancer, Biliary Tract Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07830147
Biliary Tract Cancer, Biliary Tract Diseases
Chengdu, Sichuan, China
View Trial DetailsNCT05220046
Biliary Tract Cancer, Biliary Tract Diseases
Omaha, Nebraska, United States
View Trial Details